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A B S T R A C T
The burden of human diseases in populations, or for an individual, is frequently estimated in terms of one of a
number of Health Adjusted Life Years (HALYs). The Disability Adjusted Life Year (DALY) is a widely accepted
HALY metric and is used by the World Health Organization and the Global Burden of Disease studies. Many
human diseases are of animal origin and often cause ill health and production losses in domestic animals. The
economic losses due to disease in animals are usually estimated in monetary terms. The monetary impact on
animal health is not compatible with HALY approaches used to measure the impact on human health. To esti-
mate the societal burden of zoonotic diseases that have substantial human and animal disease burden we pro-
pose methodology which can be accommodated within the DALY framework. Monetary losses due to the animal
disease component of a zoonotic disease can be converted to an equivalent metric using a local gross national
income per capita deﬂator. This essentially gives animal production losses a time trade-oﬀ for human life years.
This is the time required to earn the income needed to replace that ﬁnancial loss. This can then be assigned a
DALY equivalent, termed animal loss equivalents (ALE), and added to the DALY associated with human ill health
to give a modiﬁed DALY. This is referred to as the “zDALY”. ALEs could also be estimated using willingness-to-
pay for animal health or survey tools to estimate the replacement time value for animals with high societal or
emotional value (for example pets) that cannot be calculated directly using monetary worth. Thus the zDALY
estimates the impact of a zoonotic disease to animal and human health. The losses due to the animal disease
component of the modiﬁed DALY are straightforward to calculate. A number of worked examples such as
echinococcosis, brucellosis, Q fever and cysticercosis from a diverse spectrum of countries with diﬀerent levels of
economic development illustrate the use of the zDALY indicator.
1. Introduction
An understanding of the economic and social impacts of diseases is
central to the decision making process for disease control. Animal dis-
ease impact is widely studied using economic models based on mone-
tary costs [1–3]. Therefore animal losses can be estimated for the values
of livestock and livestock products lost through diseases [4,5]. In health
economics the cost of human disease can be quantiﬁed in terms of cost
of treatment and loss of income during convalescence in cost of illness
studies [6,7]. For example in the Netherlands the cost of illness for 14
food-related pathogens for 2011 was estimated at approximately €468
million [8]. These costs included several zoonoses such as tox-
oplasmosis, which had costs of approximately €55 million.
The calculation of a monetary burden of human ill health, to in-
corporate death and disability as well as the cost of illness, has been
criticised for a number of reasons. There is no standard methodology to
calculate the monetary value of life (or loss due to premature death)
resulting in great variability amongst diﬀerent studies [9]. This also
varies with per capita income, with the lives of individuals from high
income countries being assigned, on average, a greater monetary value.
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Indeed, this has been modelled to estimate the statistical value of life
with gross domestic product per capita as a covariate [10]. Likewise,
costs of medical treatment and loss of wages are usually higher in upper
than in lower income countries. This could perversely suggest that the
greatest economic impact of disease is in wealthy countries, despite
having higher life expectancies and lower disease incidence than low
income countries. Thus estimations of the monetary cost of disease ef-
fectively assign higher values to equivalent health outcomes in higher
income countries than to the same outcomes in the low income coun-
tries [11].
Because of these and the wider issues around valuing human life,
non-monetary population health metrics such as disability adjusted life
years (DALYs) have been developed to quantify the burden of pre-
mature death and disease and injury [12]. DALYs are calculated by
adding the number of years lived with disability adjusted for the se-
verity of the disease (YLDs) and the number of years of life lost due to
premature mortality (YLLs) [13]. DALYs have been adopted by the
WHO to quantify the global burden of disease [14] and the global
burden of foodborne diseases [15]. They can also be used in cost-ef-
fectiveness studies such as cost per DALY averted, for example rabies in
Kazakhstan [16].
In the animal health ﬁeld, there have been attempts to mirror these
burden estimates for animal diseases. There are important conceptual
diﬃculties: how to compare within and across animal species, the fact
that for livestock producers maximising their animals' life expectancy is
not necessarily a goal and that the same physical disabilities have very
diﬀerent outcomes in diﬀerent livestock productions systems. Work
sponsored by the World Bank [17] assigned livestock unit (LSU) values
to diﬀerent animal species, similar to the standard approach based on
animal weights and mapped the total units to be lost through death,
destruction or slaughter. Despite emphasizing the unevenness of and
major gaps in the data available on livestock disease impact, this study
did illustrate the relative geographical burden of fatal animal diseases.
However, it assigned the same weight to animals of a single species
across the world and did not quantify non-fatal outcomes – the pro-
duction losses which undermine the proﬁtability of livestock keeping in
many situations. For example for echinococcosis, there are no reports of
losses in China, India and much of the Middle East and North Africa in
the World Bank Atlas yet these regions are highly endemic for Echino-
coccus granulosus [18]. By contrast, the well-established methods of
animal health economics [3], allow for the impacts of animal disease,
including trade eﬀects and the cost of mitigating measures to reduce
physical losses, to be estimated in livestock across production systems
and regions, and aggregated into a single currency. By using will-
ingness-to-pay and other household survey methods, the monetary
value of companion animals and wildlife can be estimated in a range of
contexts. As well as owners' valuations, ﬁnancial awards in legal cases
are often linked to the lifetime cost of keeping companion animals and
for wildlife, other monetary considerations include their commercial
contribution to tourism.
As a non-monetary value, DALYs do not capture other societal
burdens that may not be directly human health-related. With zoonotic
diseases there is clearly potential for a human disease and an animal
disease burden, as by deﬁnition zoonoses infect both animals and hu-
mans [19]. Presently there has been no satisfactory metric developed
that can incorporate both these burdens and estimate their relative
share in the societal cost of disease. For zoonoses control projects, cost
sharing in proportion to expected disease control beneﬁts has been
proposed [20], but this is related only to the estimated monetary ben-
eﬁts in terms of animal disease prevention and monetary savings from
reduced cost of human illness, which are assessed separately from the
DALY component. To be incorporated into the DALY metric, livestock
deaths and production losses, need to be quantiﬁed into an animal
disease burden metric which can stand alongside the DALY. Such a
metric should reﬂect the impact of the animal disease on its owner in
terms of the time that might be required to replace that animal or
recoup the losses caused by its illness. Thus a subsistence farmer in sub-
Saharan Africa who loses a cow, of value $500, due to disease may
suﬀer a much greater impact than a farmer from an industrialized na-
tion who might lose a highly productive cow of value $1000. If the
former has an income of just $1000 per annum and the latter $40,000
per annum, the relative time in terms of income generation to replace
that loss would be six months for the former and 1.3 weeks for the
latter. The same approach can be extended to production losses from
non-fatal animal diseases: if the same cow on a sub-Saharan African
farm were to be infected with brucellosis it might suﬀer a 15% reduc-
tion in milk production and fertility [21] equivalent to, say, $75. In this
case the African farmer would need nearly 4 weeks to replace that loss,
whereas a farmer in an upper income country would require less than
1.5 days to replace a similar proportional loss.
These impacts can thus be viewed as time that the livestock owner
has been forced to sacriﬁce to replace the loss of his animal or to make
up for the reduced output that a non-fatal animal disease causes. In this
manuscript we propose a modiﬁed DALY for zoonotic disease, termed
zDALY, that has an additional component, termed animal loss equiva-
lents (ALE). The ALE can be estimated from the monetary value of li-
vestock losses and local per capita income by using a time trade-oﬀ
approach to estimate an equivalent burden to the human population.
The clear rationale is therefore to incorporate animal health losses into
the DALY framework to assess the burden of diseases that transmit
between animals and humans. In the DALY framework, non-fatal
human illnesses and injuries are given a disability weight (DW) and the
duration of this DW gives an equivalent number of lives lost and is
essentially a time trade-oﬀ by assigning the time lived with the dis-
ability to a shorter time of healthy years (i.e. lived without the dis-
ability). It is proposed that the ALE component in the zDALY is also
given a time equivalent of healthy years. A number of worked examples
on diﬀerent zoonotic diseases from low, middle and upper income
countries are used to illustrate this concept.
2. Materials and methods
2.1. Data
2.1.1. Cystic echinococcosis
Human cystic echinococcosis (CE) is caused by the larval stage of E.
granulosus. This results in a space occupying lesion, usually in the liver
or lungs but occasionally aﬀecting other organs such as the central
nervous system. Most species of farm livestock can be infected with
high prevalences frequently seen in sheep. CE can result in a substantial
human disease burden and have a substantial economic impact on an-
imal productivity [22,23]. In animals these include condemnation of
edible oﬀal, a lowered food conversion ratio and a decreased milk yield.
The monetary value of these eﬀects is used to estimate the ALE com-
ponent of the zDALY. Both humans and livestock become infected by
contact with infected dogs which are the deﬁnitive hosts of E. granulosus
[24]. There are a number of estimates of the impact of CE in various
countries including Iran [25], Jordan [26], Kyrgyzstan [27], Peru [28],
Spain [29] and Tunisia [30]. The raw data, converted to 2015 US$ are
presented in Table 1.
2.1.2. Brucellosis
Human brucellosis is a zoonotic bacterial disease caused by a
number of species of the genus Brucella. Human infection can result in
intermittent fever, headaches, weakness, arthralgia, myalgia, weight
loss, orchitis and spontaneous abortion [31]. In animals, brucellosis can
cause a variety of clinical manifestations, particularly abortion, long
run eﬀects on fertility and reduced milk yield, resulting in substantial
economic losses. These make up the ALEs contributing to the zDALY.
Transmission to humans occurs through the consumption of infected,
unpasteurized milk products, through direct contact with infected an-
imal parts and through the inhalation of infected aerosolized particles
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[32]. Data on human brucellosis are oﬃcially reported ﬁgures from the
Kyrgyz Ministry of Health [33]. Data for the economic impact of bru-
cellosis in animals are based on Zinsstag et al. [21].
2.1.3. Q fever
Q fever is caused by the bacterium Coxiella burnetti. Sheep, goats,
and cattle are the primary reservoirs. The most common signs of Q fever
in animals are abortion during late pregnancy or weak oﬀspring [34].
This results in the economic losses in aﬀected animals used to estimate
ALEs and hence contribute to the zDALY. Infection of humans usually
occurs by inhalation of bacteria or from ingestion of unpasteurized
dairy products. Humans present with mild ﬂu-like symptoms with oc-
casional complications such as endocarditis. There was an epidemic of
Q fever in the Netherlands with cases peaking in 2009 [35]. The esti-
mated economic costs of the outbreak and the burden of disease in
terms of DALYs have been estimated [34,36].
2.1.4. Cysticercosis
Taenia solium causes cysticercosis in pigs and neurocysticercosis in
humans. The former can lead to substantial livestock losses whilst the
latter can result in a number of neurological syndromes such as epilepsy
[37]. Human cysticercosis results from faecal-oral contamination with
T. solium eggs from tapeworm carriers [38]. The dual monetary impact
to animal production and human health burden in terms of DALYs has
been estimated for West Cameroon [39]. Here it was assumed that in-
fection with cysticercosis reduced the value of pigs by 30% and this was
the basis for estimating the ALE component of the zDALY. The data
from this report are used to estimate the number of zDALY due to T.
solium cysticercosis.
2.2. zDALY
To calculate the zDALY, information on the incidence of human
disease of interest together with the natural history of the disease and
the morbidity and mortality rates are required. The degree of morbidity
is required to estimate the DWs and the duration to estimate the YLDs
[40]. Numbers of fatal cases, stratiﬁed by age are required for the YLLs.
For the ALE component information about the morbidity and mortality
in livestock or other domestic animals is required in addition to the
local value of these animals and their products. The income per head of
the human population is also necessary to estimate a time trade-oﬀ for
an economic loss due to animal disease. For animals that have no ob-
vious commercial value, household survey methods, such as will-
ingness-to-pay, and other approaches discussed above, could be used to
estimate the time trade-oﬀ equivalent.
The human burden of disease was calculated as DALYs. Incidence-
based YLDs were calculated by multiplying the numbers of cases of
disease reported by their duration and DW. The YLLs were calculated as
the numbers of deaths and their residual life expectancy at the time of
death. Suitable DWs from the GBD 2010 study [41] were used in all
estimates. To calculate the ALEs, ﬁrst an estimate of the annual
monetary impact of the animal diseases, including production losses,
was made. These estimates were already published previously in several
of the datasets used, but were updated to 2015. This was achieved by
converting to US$ at the prevailing exchange rate at the time of the
study (http://www.x-rates.com/historical) followed by a correction for
the US$ inﬂation rate since the date of the estimates (http://www.
usinﬂationcalculator.com/). This total monetary impact of the animal
disease was then divided by the gross national per capita income (GNI)
to obtain ALEs at 2015 values.
ALE = monetary value of animal health losses/GNI per person.
In all our calculations we used nominal values converted to US$ at
the mean exchange rate in 2015 to make the estimates of ALEs.
Nominal values were selected, as all the studies used current rather
than international dollar or local currency values.
Thus zDALY = YLL + YLD+ ALE.
GNI per capita data at current dollars were according to the World
Bank ﬁgures (downloaded from http://data.worldbank.org/indicator/
NY.GNP.PCAP.CD).
3. Results
Table 2 gives the estimated ALEs for echinococcosis in diﬀerent
countries, whilst Table 3 gives the DALYs and incident zDALYs. The
relative contribution to the zDALY from DALYs and ALEs varies be-
tween diﬀerent countries. For echinococcosis in Iran for example, most
of the burden is from the livestock sector. In Peru the opposite is the
case. This is illustrated in Fig. 1. The monetary losses due to echino-
coccosis vary from $4.4 million/year for Peru, to $143 million/year for
Iran (Table 1). However, when adjusted for purchasing parity and
converted into ALEs, Spain, for example, incurs just 904 ALEs, com-
pared to Kyrgyzstan which incurs 4795 ALEs (Table 2). This is despite
the fact that the gross economic loss in Spain is $25.8 million, some four
times that of Kyrgyzstan of $5.5 million (Table 1).
For brucellosis in Kyrgyzstan 90% of the societal burden is from
animal losses (Table 4, Fig. 2). This compares to about 31% for Q fever
in the Netherlands, but under 1% for cysticercosis in West Cameroon. In
the Netherlands, Q fever had a monetary impact on animal health of
approximately $122 million. This was more than ten times higher than
the monetary impact of brucellosis in livestock in Kyrgyzstan. However,
in terms of ALEs, there was a much higher impact in Kyrgyzstan with
10,085 ALEs (170 per 100,000 people) compared to 2537 (15 per
100,000 in the Netherlands).
4. Discussion
DALYs reﬂect only the importance of human disease or injury to
Table 1
Data used to estimate the zDALY for cystic echinococcosis (CE).
Year Animal lossesa US$ 2015 equivalent GNI per capita 2015 Treatment-seeking human cases/annum Non treatment-seeking human cases/annum
Iran 2010 $132 million $143 million $6550 922 937
Jordan 2001 $3.58 million $4.82 million $4680 187 200
Kyrgyzstan 2013 $5.5 million $5.6 million $1170 884 1226
Peru 2007 $3.85 million $4.40 million $6130 2890 4380
Spain 2005 €15.5million $25.8 million $28,530 208 208
Tunisia 2000 $8.38 million $11.45 million $3980 1339 1127
a As reported in [25–30].
Table 2
Animal loss equivalents (ALEs): CE.
Human population ALEs ALEs/100,000 person years
Iran 79.1 million 21,832 27.6
Jordan 7.59 million 1030 13.5
Kyrgyzstan 5.94 million 4786 80.6
Peru 31.8 million 718 2.3
Spain 46.1 million 904 2.0
Tunisia 11.3 million 2877 25.5
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society. Zoonotic diseases can have adverse outcomes for both human
and animal subjects. We have proposed the zDALY to quantify this. This
also takes into account time lost due to animal morbidity and mortality.
As for the DALY, our focus in this quantiﬁcation of both human and
animal losses is on the impact of morbidity and mortality: we do not
consider the wider prevention and treatment costs of ill health in people
and animals and we restrict the burden of human disease to the DALY
component. The essential component to include animal health losses is
converting monetary losses due to animal disease into time lost to so-
ciety. This is achieved by equating it to the time needed to earn the
income to recover that loss. Time trade-oﬀs are one method used to
estimate the value of health states when calculating Quality Adjusted
Life Years (QALYs) [43]. Therefore the same concept could indeed be
applied to QALY losses. However our focus is on the DALY as this is the
most common HALY metric for quantifying burden of disease. Also,
DALYs were originally formulated from a disease perspective, while
QALYs were formulated from a patient perspective. As the addition of
livestock losses is proposed for quantifying the disease burden of spe-
ciﬁc diseases, the perspective coincides with that of the DALY.
Although time trade-oﬀs have been used to estimate DWs for DALYs
[44,45], in GBD 2010 DWs for DALY calculations were developed
through household surveys. These asked respondents paired compar-
ison questions, in which respondents considered two hypothetical in-
dividuals with diﬀerent, randomly selected health states and indicated
which person they regarded as healthier. A further survey included
questions about population health equivalence for a subset of 30 health
states. In these questions, respondents were asked to compare the
health beneﬁts of diﬀerent life-saving or disease-prevention pro-
grammes to anchor disability weights to the necessary scale (from zero
to one) [41]. It would also be possible to undertake similar household
surveys to determine equivalences of monetary losses with health
states, but these would need to be controlled for local income levels.
Furthermore, we use monetary values of livestock losses purely as a
technique to estimate the time trade-oﬀ to calculate the ALE. Some
animals such as a treasured domestic pet or an animal of great religious
signiﬁcance may have a value to the owner far greater than its com-
mercial worth. Such issues can still be addressed by household surveys
to gauge how these are valued. The ALE could then be calculated for the
respective species based on the results of such surveys.
The strength of our approach is that it values diﬀerent monetary
Table 3
Burden of disease for CE in terms of DALYs and zDALYs.
Source: data from WHO Foodborne Disease Burden Epidemiology Reference
Group (FERG) [42].
YLDs YLLs DALYs DALYs/
100,000
person years
ALEs/
100000
person years
zDALY/
100,000
person years
Iran 537 1198 1735 2.19 27.6 29.8
Jordan 113 250 363 4.78 13.5 18.3
Kyrgyzstan 573 1258 1831 30.8 80.6 111
Peru 1943 4185 6128 19.3 2.3 21.6
Spain 126 271 397 0.86 2.0 2.86
Tunisia 758 1689 2447 21.7 25.5 47.2
Fig. 1. Top: Estimated number ofzDALYs per 100,000 population for echinococcosis in various countries. Bottom: proportion of zDALY contributed by YLDs, YLLs
and ALEs.
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losses in terms of their local impact. For example, in Spain the monetary
loss due to echinococcosis is approximately $56,000 per 100,000
person years. In Peru it is $14,000 per 100,000 person years. However,
because Peru has a considerably lower per capita income, there is a
higher burden of ALEs in Peru (2.3 per 100,000 person years) compared
to Spain (2.0 per 100,000 person years). Thus ALEs have the desirable
property of being linked to the actual impact of the losses felt to the
population. It may be that ultimately an ALE is considered to be of less
value than a whole life year – a person may value their working time at
say, only half their time. Such equivalences could be further explored
and nuanced once the concept of the ALE has gained some traction. A
potential limitation of our approach is that for the ALE component our
examples examine direct losses due to mortality and morbidity (con-
verted to a time trade-oﬀ) and there are other aspects, such as inter-
vention costs. However, it thus remains analogous to estimating DALYs
where costs of treatment or control are not included in the metric.
Therefore comparable and analogous data must be used for estimating
the ALE and DALY components of the zDALY.
There have been attempts to put a monetary value on a DALY [46].
In the context of zoonotic disease, we propose the opposite by giving a
local monetary loss due to livestock disease an equivalent DALY. It may
be possible to extend this approach to estimating the impact of animal
diseases that are not zoonoses. An example would be the foot and
mouth disease (FMD) outbreak in the United Kingdom in 2001. Over 6
million animals were slaughtered resulting in approximately £3.1 bil-
lion ($4.5 billion) losses to agriculture and the food chain [47]. The GNI
per person in the UK in 2001 was $26,300, so the impact in terms of
ALEs would be approximately 170,000. This considerable number of
DALY equivalents would reﬂect the devastation caused to UK agri-
culture during the outbreak. Another possible extension of the approach
would be to set it in a wider One Health framework, looking at eco-
system impacts, such as the time equivalent required for an ecosystem
to recover from damage.
The zDALY can, like the DALY, be used in priority-setting across
sectors. In cost-eﬀectiveness studies the cost per zDALY averted can be
used to compare diﬀerent interventions for the same disease, or more
broadly to compare the cost-eﬀectiveness of control compared to the
cost-eﬀectiveness of other competing public health projects. It may
improve the eﬃciency of resource allocation as the zDALY accounts for
the often substantial societal impact to animal health of zoonotic dis-
eases. This is particularly true in marginalised communities which
subsist on small numbers of livestock. In poor countries, diseases kill
many animals. In 2009 a total of 2.1 million cattle and 13.1 million
sheep died of disease in just three sub-Saharan African countries:
Burkina Faso, Mali and Niger. This represented a direct loss of 5.5% of
total GDP [48]. Losses from other livestock and indirect losses would
further substantially inﬂate this ﬁgure. Furthermore, half of the world's
hungry are smallholder farmers who depend on agriculture for their
livelihood [49]. Thus the loss due to disease of an agricultural animal
can have a devastating eﬀect on such smallholders. The DALY does not
take this into account, as the metric only analyses the burden of human
disease. Thus the zDALY could be a valuable tool in public health
economics priority setting. For example, data from the GBD 2010 study
would ideally “be supplemented with additional information regarding
the impact of diﬀerent conditions on the health and welfare of in-
dividuals in diﬀerent locales” [50]. The zDALY provides such in-
formation on the impact of animal disease and could also potentially
drive sustainable development action. By anchoring disease losses
ﬁrmly in relation to DALYs for people and in terms of local monetary
losses for animals this joint metric is clear and transparent to both the
animal and human health constituency, while providing an aggregate
metric of the relative losses incurred.
In 2011, the Disease Reference Group on Zoonoses and Marginalised
Infectious Diseases (DRG6), convened by the Special Programme for
Table 4
Burden of other diseases.
Country Disease Animal losses US$ 2015
equivalents
Human
cases
DALYs DALYs/100,000
person years
ALEs ALEs/100,000 person
years
zDALYs/100,000
person years
Kyrgyzstan+ Brucellosis $10 million $11.8 million 3350 1075 18 10,085 170 188
Netherlandsa Q fever €85million $124 million 4107 5797 34 2537 15 49
West Cameroonb Cysticercosis €478.838 $794.842 18,268 45,838 9050 602 12 9061
+DALY estimate from FERG data [42] (DALYs per case).
a Q fever outbreak – data from [34–36], duration of outbreak 2007–2011.
b Data from [39].
Fig. 2. Proportion of zDALY contributed by the standard DALY and ALE by brucellosis in the Kyrgyz Republic, Q fever in the Netherlands and cysticercosis in West
Cameroon.
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Research and Training in Tropical Diseases (TDR), identiﬁed nine
macro research priorities related to zoonotic diseases of marginalised
populations [51]. One of these priorities was the development of a
comprehensive methodology for calculating the societal burden of
disease attributable to zoonoses. The zDALY metric provides a
straightforward, practical and rigorous answer to this need.
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